Get started
Author

Christelle Pommie

IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains
2002 · Marie-Paule Lefranc, Christelle Pommié, et al. · Developmental & Comparative Immunology · 831
PDF
IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains
2004 · Marie-Paule Lefranc, Christelle Pommié, et al. · Developmental & Comparative Immunology · 811
Effect of Music Therapy on Anxiety and Depression in Patients with Alzheimer’s Type Dementia: Randomised, Controlled Study
2009 · S. Guétin, F. Portet, et al. · Dementia and Geriatric Cognitive Disorders · 449
IMGT standardized criteria for statistical analysis of immunoglobulin V‐REGION amino acid properties
2004 · Christelle Pommié, Séverine Levadoux, et al. · Journal of Molecular Recognition · 322
The Effects of Music Intervention in the Management of Chronic Pain
2011 · Stéphane Guétin, Patrick Giniès, et al. · Clinical Journal of Pain · 154
IMGT-ONTOLOGY for immunogenetics and immunoinformatics.
2004 · Marie-Paule Lefranc, Véronique Giudicelli, et al. · PubMed · 95
Beliefs and Attitudes of French Family Practitioners toward Depression: The Impact of Training in Mental Health
2011 · Joanna L. Norton, Christelle Pommié, et al. · The International Journal of Psychiatry in Medicine · 22
Pure-Tone Threshold Description of an Elderly French Screened Population
2008 · Catherine Blanchet, Christelle Pommie, et al. · Otology & Neurotology · 18
Abstracts from the 10th C1-inhibitor deficiency workshop
2017 · on behalf of COMPACT investigators, Alvin H. Schmaier, et al. · Allergy Asthma and Clinical Immunology · 9
PDF
THU-135 Real-world study of reasons for non-utilization of second-line treatment in patients with primary biliary cholangitis
2024 · Seema T. Meloni, Claudia O. Zein, et al. · Journal of Hepatology · 4
PREF-NET: a patient preference and experience study of lanreotide autogel administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumours in the UK
2024 · Mohid S. Khan, Kathryn Cook, et al. · Supportive Care in Cancer · 3
PDF
An international simulated-use study to assess nurses’ preferences between two lanreotide syringes for patients with neuroendocrine tumours or acromegaly (PRESTO 3)
2023 · D. Ferone, W. Martin, et al. · Journal of Endocrinological Investigation · 3
PDF
Burden of Comorbidities and Concomitant Medications and Their Associated Costs in Patients with Gastroenteropancreatic or Lung Neuroendocrine Tumors: Analysis of US Administrative Data
2025 · Jennifer A. Chan, Antonio Ribeiro-Oliveira, et al. · Advances in Therapy · 1
P35 Elafibranor treatment in real-world practice: interim results from a UK subgroup analysis of the prospective, non-interventional ELFINITY phase IV global study in patients with primary biliary cholangitis
2026 · Jessica Katharine Dyson, Lynsey Corless, et al. · Gut
PDF
EP1035 - ECE_2423 - Real-world effectiveness and safety of lanreotide autogel in patients with acromegaly in China: primary results and post-hoc analysis from a multicenter prospective observational study
2026 · Lian Duan, Songyun Zhang, et al. · European Journal of Endocrinology
PDF
LBP-033 Elafibranor treatment results in rapid reductions in biochemical markers and symptom burden in real-world practice: interim results from the prospective, non-interventional ELFINITY phase IV global study in patients with primary biliary cholangitis
2026 · Jörn M. Schattenberg, Peter Fickert, et al. · Journal of Hepatology
LBP-023 Real-world outcomes in patients with primary biliary cholangitis who initiated elafibranor treatment with baseline alkaline phosphatase levels between 1× to 1.67× the upper limit of normal
2026 · Cynthia Levy, Channa Jayasekera, et al. · Journal of Hepatology
Elafibranor treatment results in rapid reductions in biochemical markers and symptom burden in real-world practice: interim results from the prospective, non-interventional ELFINITY phase IV global study in patients with primary biliary cholangitis
2026 · J Schattenberg, P Fickert, et al. · Zeitschrift für Gastroenterologie
1720P Secondary results from KINETICS, a real-world study of lanreotide autogel (LAN) in advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) according to Ki67 proliferation index (Ki67)
2025 · T. Walter, P.R. Steinhagen, et al. · Annals of Oncology
210P KINETICS: Real-world study of lanreotide autogel (LAN) in advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) according to Ki67 proliferation index (Ki67)
2025 · T. Vandamme, P.R. Steinhagen, et al. · Annals of Oncology
A real-world study of lanreotide autogel for the treatment of patients with acromegaly in china: baseline interim analysis
2025 · Huijuan ZHU, Ting Lei, et al. · Endocrine Abstracts
S1827 Elafibranor for the Treatment of Primary Biliary Cholangitis: Study Designs of the ELFIDENCE, ELSPIRE, and ELFINITY Phase III/IV Trials
2024 · Marcelo Kugelmas, Kris V. Kowdley, et al. · The American Journal of Gastroenterology
PRESTO 3: An international, simulated-use study assessing preferences of nurses between two lanreotide syringes (Somatuline® Autogel® vs Pharmathen)
2023 · Diego Ferone, Wendy Martin, et al. · Endocrine Abstracts
THU062 PRESTO 3: A Simulated-use Study Assessing Preferences Of Nurses In The USA And Europe Between Two Lanreotide Syringes (Somatuline Autogel Vs Pharmathen)
2023 · Jessica Williams, Diego Ferone, et al. · Journal of the Endocrine Society
An international, simulated-use study assessing nurses' preferences between two lanreotide syringes (Somatuline Autogel vs Pharmathen) for treatment of neuroendocrine tumours (NETs) and/or acromegaly: PRESTO 3
2023 · Diego Ferone, Wendy Martin, et al. · Endocrine Abstracts
Works count: 31
Citation count: 2,722
H-index: 9
I10-index: 8
Year
Topic
Type